Abril - 2017

ienov

330

ssoc

ras

2017; 63(4):324-331

in other studies in men is a reflection of lower HDL-cho-

lesterol levels. Another limitation for assessing this rela-

tionship is the study design, which is cross-sectional. In

a longitudinal study performed with a larger number of

non-diabetic Ob-II,III,MetS patients with PPN, other as-

sociations or risk factors might be found. Therefore,

cross-sectional studies with a larger sample and a higher

number of men, as well as longitudinal studies, would

be necessary to confirm that PPN is associated with low

serum HDL-cholesterol and whether there are other as-

sociated risk factors for PPN in these patients.

onclusion

Our study revealed an 11% prevalence of PPN in indivi-

duals with obesity grade II and III with MetS and not

diagnosed with diabetes, and the presence of PPN was

independently associated with low HDL-cholesterol levels.

Since an increase in HDL-cholesterol is rarely achieved

with the treatment of these patients, PPN often progres-

ses in these cases, especially in patients that will become

hyperglycemic or develop DM. In order to diagnose this

complication, a neurological evaluation should be done

when patients come for outpatient visits.

esumo

Polineuropatia periférica em pacientes obesos graves com

síndrome metabólica sem diabetes: associação com baixo

HDL-colesterol

Objetivo:

Avaliar a prevalência da polineuropatia perifé-

rica (PNP) em indivíduos obesos graus II e III com sín-

drome metabólica (Ob-II,III,SM) sem diabetes e buscar

possíveis fatores associados.

Método:

Em um estudo transversal, realizado em indiví-

duos Ob-II,III,SM e sem diagnóstico de diabetes, o Ins-

trumento de Screening de Michigan (MNSI) foi utilizado

para avaliar a presença de PNP.

Resultados:

Um total de 24 de 218 pacientes Ob-II,III,SM

e sem diabetes tinham PNP. Quando observamos as as-

sociações com PNP em uma análise univariada, níveis

séricos de LDL-colesterol (p=0.046) estiveram significa-

tivamente associados e houve também uma tendência à

associação com níveis séricos de triglicerídeos (p=0.118)

e baixo HDL-colesterol (p=0.057). Em uma análise de

regressão de Poisson, quando as três possíveis associações

foram incluídas, baixo HDL-colesterol (p=0.047) mante-

ve-se independentemente associado.

Conclusão:

Em pacientes Ob-II,III,SM, mas sem diabetes,

a PNP definida pelo MNSI tem uma prevalência elevada

e está associada a baixos níveis de HDL-colesterol. Para

diagnóstico dessa complicação, recomenda-se realizar o

exame neurológico desses pacientes.

Palavras-chave:

polineuropatias, obesidade, síndrome

metabólica, HDL-colesterol.

eferences

1. The effect of intensive treatment of diabetes on the development and

progression of long-term complications in insulin-dependent diabetes

mellitus. The Diabetic Control and Complications Trial Research Group.

N Engl J Med. 1993; 329(14):977-86.

2. The effect of intensive diabetes therapy on the development and progression

of neuropathy. The Diabetic Control and Complications Trial Research

Group. Ann Intern Med. 1995; 122(8):561-8.

Intensive blood-glucose control with sulphonylureas or insulin compared

with conventional treatment and risk of complications in patients with type

2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Lancet. 1998; 352(9131):837-53.

4. World Health Organization. What is overweight and obesity? Geneva: WHO;

2016.

International Diabetes Federation. IDF Worldwide definition of the Metabolic

Syndrome; 2015. Available from:

http://www.idf.org/metabolic-syndrome.

6. American Diabetes Association. Classification and Diagnosis of Diabetes.

Diabetes Care. 2016; 39 (Suppl 1):S13-22.

Buchsbaum DG, Buchanan RG, Centor RM, Schnoll SH, Lawton MJ.

Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann

Intern Med. 1991; 115(10):774-7.

8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum

creatinine. Nephron. 1976; 16(1):31-41.

Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW,

et al.; DCCT/EDIC Research Group. Use of the Michigan Neuropathy

Screening Instrument as a measure of distal symmetrical peripheral

neuropathy in Type 1 diabetes: results from the Diabetes Control and

Complications Trial/Epidemiology of Diabetes Interventions and

Complications. Diabet Med. 2012; 29(7):937-44.

10.

Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy

screening instrument for diabetic peripheral neuropathy. Clin Neurol

Neurosurg. 2006; 108(5):477-81.

11.

Russell JW, Feldman EL. Impaired glucose tolerance – does it cause

neuropathy? Muscle Nerve. 2001; 24(9):1109-12.

12. Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral

neuropathy in individuals with cardiometabolic clustering and obesity:

National Health and Nutrition Examination Survey 2001-2004. Diabetes

Care. 2011; 34(7):1642-7.

13.

Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired

glucose tolerance in patients with painful sensory neuropathy. Diabetes

Care. 2001; 24(8):1448-53.

14.

Smith AG, Singleton JR. The diagnostic yield of a standardized approach

to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;

164(9):1021-5.

15.

Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA

Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes

is associated with abdominal obesity and macroangiopathy: the

MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;

31(3):464-9.

16.

Katon JG, Reiber GE, Nelson KM. Peripheral neuropathy defined by

monofilament insensitivity and diabetes status: NHANES 1999-2004.

Diabetes Care. 2013; 36(6):1604-6.

17.

Smith AG. Impaired glucose tolerance and metabolic syndrome in idiopathic

neuropathy. J Peripher Nerv Syst. 2012; 17(Suppl 2):15-21.

18. Callaghan B, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffet H, et al. Tri-

glycerides and amputation risk in patients with diabetes: ten-year follow-

-up in the DISTANCE study. Diabetes Care. 2011; 34(3):635-40.

19. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste

C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;

352(4):341-50.